Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Wall Street Zen lowers KNSA rating from “strong-buy” to “buy” in latest note.
  • Jefferies, Wedbush, and Wells Fargo maintain buy outlook with higher price targets.
  • Analysts project FY 2025 EPS of -0.55 despite quarterly earnings beat.

Kiniksa Pharmaceuticals International (NASDAQ: KNSA) received a rating downgrade from Wall Street Zen, shifting from a “strong-buy” to a “buy” recommendation in a recent research note issued on Saturday. This adjustment reflects a slightly more cautious stance from analysts, although sentiment toward the stock remains broadly positive.

Other research firms continue to maintain favorable outlooks for Kiniksa. Jefferies Financial Group recently raised its price target from USD45.00 to USD54.00 while reiterating a “buy” rating in late July. Similarly, Wedbush reiterated its “outperform” rating with a USD36.00 price target, and Wells Fargo & Company increased its target from USD30.00 to USD42.00 while assigning an “overweight” rating earlier in the month. Based on data from MarketBeat.com, the stock currently carries a consensus rating of “Buy” with an average price target of USD41.17.

The company reported its latest quarterly results on July 29th, delivering earnings per share (EPS) of USD0.23, which exceeded analysts’ consensus estimate of USD0.18 by USD0.05. Revenue for the quarter came in at USD156.80 million, above the expected USD145.21 million. Kiniksa posted a return on equity of 1.05% and a net margin of 0.90%, signaling narrow profitability.

Looking ahead, analysts project a full-year EPS of -0.55, indicating expected losses for the current fiscal year despite the recent earnings beat. Investors may watch the company’s upcoming guidance updates for clarity on its development pipeline, which includes ARCALYST for recurrent pericarditis, Mavrilimumab for giant cell arteritis, Vixarelimab for prurigo nodularis, and KPL-404 targeting immune-mediated diseases.